Federal Register / Vol. 80, No. 17 / Tuesday, January 27, 2015 / Notices 4267 

interconnectedness, or the mix of 

activities of the nonbank financial 

company, could pose a threat to 

financial stability. On April 11, 2012, 

the Council published in the Federal 

Register a final rule and interpretive 

guidance (77 FR 21637), 12 CFR part 

1310, that describe the manner in which 

the Council intends to apply the 

statutory standards and considerations, 

and the processes and procedures the 

Council intends to follow, in making 

determinations under Section 113 of the 

Dodd-Frank Act. The Council has made 

final determinations regarding four 

nonbank financial companies. The 

Council uses information collected 

under 12 CFR 1310.20 to assess whether 

a nonbank financial company meets the 

standards for a Council determination 

under Section 113 of the Dodd-Frank 

Act. The collection of information under 

12 CFR 1310.21 affords a nonbank 

financial company an opportunity to 

submit materials to contest the 

Council’s consideration of the company 

for a proposed determination and to 

contest a proposed determination. The 

collection of information in 12 CFR 

1310.22 provides a nonbank financial 

company an opportunity to contest the 

Council’s waiver or modification of the 

notice or other procedural requirements 

contained in 12 CFR 1310.21 by 

requesting a hearing. The Council uses 

information collected under 12 CFR 

1310.23 in a reevaluation of its 

determination regarding a nonbank 

financial company subject to a Council 

determination. 

DATES: Written comments must be 

received on or before March 30, 2015 to 

be assured of consideration. 

ADDRESSES: You may submit comments 

by any of the following methods: 

Mail: Attn: Request for Comments 

(Financial Stability Oversight Council 

Proposed Information Collection), Office 

of the Financial Stability Oversight 

Council, Department of the Treasury, 

1500 Pennsylvania Avenue NW., 

Washington, DC 20220. 

Electronic Submission: 

FSOC.Comments@treasury.gov. 

Instructions: All submissions received 

must include the agency name and the 

Federal Register document number that 

appears at the end of this document. 

Comments received will be made 

available to the public via 

regulations.gov without change, and 

including any personal information 

provided. 

FOR FURTHER INFORMATION CONTACT: 

Requests for additional information 

about the filings or procedures should 

be directed to Executive Director, 

Financial Stability Oversight Council, 

Department of the Treasury, 1500 

Pennsylvania Avenue NW., Washington, 

DC 20220. 

SUPPLEMENTARY INFORMATION: 

Title: Determinations Regarding 

Certain Nonbank Financial Companies. 

OMB Control Number: 1505–0244. 

Abstract: The Council uses 

information collected under 12 CFR 

1310.20 to assess whether a nonbank 

financial company meets the standards 

for a Council determination under 

Section 113 of the Dodd-Frank Act. The 

collection of information under 12 CFR 

1310.21 affords a nonbank financial 

company an opportunity to submit 

materials to contest the Council’s 

consideration of the company for a 

proposed determination and to contest a 

proposed determination. The collection 

of information in 12 CFR 1310.22 

provides a nonbank financial company 

an opportunity to contest the Council’s 

waiver or modification of the notice or 

other procedural requirements 

contained in 12 CFR 1310.21 by 

requesting a hearing. The Council uses 

information collected under 12 CFR 

1310.23 in its reevaluation of a 

determination regarding a nonbank 

financial company subject to a Council 

determination. 

Type of Review: Extension of a 

currently approved collection. 

Affected Public: Nonbank financial 

companies. 

Estimated Total Annual Burden 

Hours for all Collections: 500 hours. 

Request for Comments: Comments 

submitted in response to this notice will 

be summarized or included in the 

request for OMB approval. All 

comments will become a matter of 

public record. Comments are invited on: 

(a) Whether the collection of 

information is necessary for the proper 

performance of the functions of the 

agency, including whether the 

information has practical utility; (b) the 

accuracy of the agency’s estimate of the 

burden of the collection of information; 

(c) ways to enhance the quality, utility, 

and clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. 

David G. Clunie, 

Executive Secretary. 

[FR Doc. 2015–00860 Filed 1–26–15; 8:45 am] 

BILLING CODE 4810–25–P–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Findings of Research Misconduct 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that 

the Office of Research Integrity (ORI) 

has taken final action in the following 

case: 

Dong Xiao, Ph.D., University of 

Pittsburgh: Based on the report of an 

inquiry conducted by the University of 

Pittsburgh (UP), additional analysis 

conducted by ORI in its oversight 

review, and an admission by the 

Respondent that he had ‘‘intentionally 

fabricated data contained in a paper 

entitled ‘Guggulsterone inhibits prostate 

cancer growth via inactivation of Akt 

regulated by ATP citrate signaling,’ 

specifically Figure 6G,’’ ORI found that 

Dr. Dong Xiao, former Research 

Assistant Professor, Department of 

Urology, UP, engaged in research 

misconduct in research supported by 

National Cancer Institute (NCI), 

National Institutes of Health (NIH), 

grant R01 CA157477. 

ORI found that Respondent engaged 

in research misconduct by reporting 

falsified data in Figures 1, 4, 5, S2, and 

S3 in the following paper published 

online: 

• Gao, Y., Zeng, Y., Tian, J., Kslam, 

M.S., Jiang, G., & Xiao, D., 

‘‘Gugglesterone inhibits prostate cancer 

growth via inactivation of Akt regulated 

by ATP citrate signaling.’’ Oncotarget, 

June 26, 2014 [Epub ahead of print], 

PMID: 24980815; hereafter referred to as 

the ‘‘Oncotarget paper.’’ 

Specifically, in the Oncotarget paper, 

Respondent: 

• Falsely stated that 10 mice per group 

were used to obtain data for tumor 

volume (Figure 1A) and tumor weight 

(Figure 1B) when data for only four 

mice per group were available 

• falsified the results for C-caspase 3 

and phosphorylated Akt in the 

Western blots presented in Figure 1D 

to claim that treatment of tumor 

bearing mice with Z-Gug significantly 

enhanced C-capase 3 activity and 

significantly inhibited Akt 

phorphorylation, while the original 

data showed no significant effect for 

either activity 

• falsified Figure 4C by manipulating pAkt bands to show that Z-Gug alone 

and in combination with PHTM 

significantly inhibited Akt 

phosphorylation in PC3 and LNCaP 

human prostate cancer cell lines; the 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
4268 Federal Register / Vol. 80, No. 17 / Tuesday, January 27, 2015 / Notices 

numbers above each band 

representing the fold change human 

prostate cancer cell lines; the numbers 

above each band representing the fold 

change in expression relative to the 

DMSO control also were falsified for 

p-ACLY (LNCaP cell line) and p-Akt 

(PC3 and LNCaP cell lines) compared 

to the values provided to the 

Respondent 

• falsified Figure 4D by substituting 

bands for p-ACLY for those provided 

to him to allow Respondent to claim 

that Z-Gug significantly inhibited 

phosphorylation of ACLY in lysates of 

prostate tumors obtained from mice, 

when the original data showed no 

effect 

• falsified Figures 5C and 5D to show 

that treatment of PC3 and LNCaP cells 

with Z-Gug alone and with Z-Gug 

plus si-RNA targets to ACLY 

stimulated Caspase 3/7 activity, when 

the original data provided to him 

showed no significant effect of either 

treatment in PC3 cells and no effect of 

Z-Gug alone in LNCaP cells 

• falsified Figures 6G and 6H; these 

figures purported to show that Nacetyl-L-cysteine (NAC), an inhibitor 

of reactive oxygen species (ROS), 

reversed the inhibition of Akt 

phosphorylation caused by Z-Gug in 

PC3 cells (Figure 6G) and LNCaP cells 

(Figure 6G) when no Akt data for this 

protocol was available to the 

Respondent; Respondent admitted to 

falsifying Figure 6G 

• falsified Figures S2B and S3B by 

altering data provided to him; these 

experiments are complementary to 

those shown in Figures 5C and 5D, 

except that the effect of Z-Gug and Zgug plus si-RNA on Caspase 3/7 

activity utilized on si-RNA was 

directed to Akt activity. The original 

data showed no significant effect of 

either treatment in PC3 cells and no 

effect of Z-Gug on LNCaP cells, while 

both treatments were claimed to be 

significant inducers of caspase 

activity in both cell lines in the 

published figures. 

Dr. Xiao has entered into a Voluntary 

Settlement Agreement (Agreement) and 

has voluntarily agreed for a period of 

three (3) years, beginning on December 

23, 2014: 

(1) To have his research supervised; 

Respondent agreed to ensure that prior 

to the submission of an application for 

U.S. Public Health Service (PHS) 

support for a research project on which 

the Respondent’s participation is 

proposed and prior to Respondent’s 

participation in any capacity on PHSsupported research, the institution 

employing him must submit a plan for 

supervision of his duties to ORI for 

approval; the plan for supervision must 

be designed to ensure the scientific 

integrity of Respondent’s research 

contribution; Respondent agreed that he 

will not participate in any PHSsupported research until such a 

supervision plan is submitted to and 

approved by ORI; Respondent agreed to 

maintain responsibility for compliance 

with the agreed upon plan for 

supervision; 

(2) that any institution employing him 

must submit, in conjunction with each 

application for PHS funds, or report, 

manuscript, or abstract involving PHSsupported research in which 

Respondent is involved, a certification 

to ORI that the data provided by 

Respondent are based on actual 

experiments or are otherwise 

legitimately derived and that the data, 

procedures, and methodology are 

accurately reported in the application, 

report, manuscript, or abstract; and 

(3) to exclude himself voluntarily 

from serving in any advisory capacity to 

PHS including, but not limited to, 

service on any PHS advisory committee, 

board, and/or peer review committee, or 

as a consultant. 

FOR FURTHER INFORMATION CONTACT: 

Acting Director, Office of Research 

Integrity, 1101 Wootton Parkway, Suite 

750, Rockville, MD 20852, (240) 453– 

8200. 

Donald Wright, 

Acting Director, Office of Research Integrity. 

[FR Doc. 2015–01427 Filed 1–26–15; 8:45 am] 

BILLING CODE 4150–31–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Notice of Interest Rate on Overdue 

Debts 

Section 30.18 of the Department of 

Health and Human Services’ claims 

collection regulations (45 CFR part 30) 

provides that the Secretary shall charge 

an annual rate of interest, which is 

determined and fixed by the Secretary 

of the Treasury after considering private 

consumer rates of interest on the date 

that the Department of Health and 

Human Services becomes entitled to 

recovery. The rate cannot be lower than 

the Department of Treasury’s current 

value of funds rate or the applicable rate 

determined from the ‘‘Schedule of 

Certified Interest Rates with Range of 

Maturities’’ unless the Secretary waives 

interest in whole or part, or a different 

rate is prescribed by statute, contract, or 

repayment agreement. The Secretary of 

the Treasury may revise this rate 

quarterly. The Department of Health and 

Human Services publishes this rate in 

the Federal Register. 

The current rate of 101⁄2%, as fixed by 

the Secretary of the Treasury, is certified 

for the quarter ended December 31, 

2014. This rate is based on the Interest 

Rates for Specific Legislation, ‘‘National 

Health Services Corps Scholarship 

Program (42 U.S.C. 250(B)(1)(A))’’ and 

‘‘National Research Service Award 

Program (42 U.S.C. 288(c)(4)(B)).’’ This 

interest rate will be applied to overdue 

debt until the Department of Health and 

Human Services publishes a revision. 

Dated: January 15, 2015. 

David C. Horn, 

Director, Office of Financial Policy and 

Reporting. 

[FR Doc. 2015–01429 Filed 1–26–15; 8:45 am] 

BILLING CODE 4150–04–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the Presidential Advisory 

Council on HIV/AIDS 

AGENCY: Office of the Assistant 

Secretary for Health, Office of the 

Secretary, Department of Health and 

Human Services. 

ACTION: Notice. 

SUMMARY: As stipulated by the Federal 

Advisory Committee Act, the U.S. 

Department of Health and Human 

Service (DHHS) is hereby giving notice 

that the Presidential Advisory Council 

on HIV/AIDS (PACHA) will hold a 

meeting to discuss essential health 

benefits and provider networks, the 

integration of the Affordable Care Act 

(ACA) qualified health plan and the 

Ryan White Program; an update on the 

National HIV/AIDS Strategy; and a 

discussion on surveillance data. The 

meeting will be open to the public. 

DATES: The meeting will be held on 

February 12, 2015, from 9 a.m. to 

approximately 5 p.m. (ET) and February 

13, 2015, from 9:30 a.m. to 

approximately 12:30 p.m. (ET). 

ADDRESSES: Renaissance Washington 

DC, Downtown Hotel, 999 Ninth Street 

NW., Washington, DC 20001. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Caroline Talev, Public Health Analyst, 

Presidential Advisory Council on HIV/ 

AIDS, U.S. Department of Health and 

Human Services, 200 Independence 

Avenue SW., Room 443H, Washington, 

DC 20201; (202) 205–1178. More 

detailed information about PACHA can 

be obtained by accessing the PACHA 

Web page on the AIDS.Gov Web site at 

www.aids.gov/pacha. 


asabaliauskas on DSK5VPTVN1PROD with NOTICES